AbstractWhile conventional parameters used to detect hepatotoxicity in drug safety assessment studies are generally informative, the need remains for parameters that can detect the potential for hepatotoxicity at lower doses and/or at earlier time points. Previous work has shown that metabolite profiling (metabonomics/metabolomics) can detect signals of potential hepatotoxicity in rats treated with doxorubicin at doses that do not elicit hepatotoxicity as monitored with conventional parameters. The current study extended this observation to the question of whether such signals could be detected in rats treated with compounds that can elicit hepatotoxicity in humans (i.e., drug-induced liver injury, DILI) but have not been reported to do so ...
New human pharmaceuticals are required by law to be tested in pre-clinical studies in order to predi...
This study investigated whether integrated analysis of transcriptomics and metabolomics data increas...
This study investigated whether integrated analysis of transcriptomics and metabolomics data increas...
<div><p>Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the dru...
In preclinical stages of drug development, anticipating potential adverse drug effects such as toxic...
Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the drug develo...
In preclinical stages of drug development, anticipating potential adverse drug effects such as toxic...
Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the drug develo...
AbstractIt has been estimated that 10% of acute liver failure is due to “idiosyncratic hepatotoxicit...
Around 40% of drug-induced liver injury (DILI) cases are not detected in preclinical studies using t...
Toxicity studies, among them hepatotoxicity, are key throughout preclinical stages of drug developme...
Current in vitro models for hepatotoxicity commonly suffer from low detection rates due to incomplet...
A new approach was evaluated to predict the hepatotoxic potential of pharmaceuticals. For this purpo...
Drug-induced liver injury (DILI) is a major safety issue during drug development, as well as the mos...
New human pharmaceuticals are required by law to be tested in pre-clinical studies in order to predi...
New human pharmaceuticals are required by law to be tested in pre-clinical studies in order to predi...
This study investigated whether integrated analysis of transcriptomics and metabolomics data increas...
This study investigated whether integrated analysis of transcriptomics and metabolomics data increas...
<div><p>Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the dru...
In preclinical stages of drug development, anticipating potential adverse drug effects such as toxic...
Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the drug develo...
In preclinical stages of drug development, anticipating potential adverse drug effects such as toxic...
Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the drug develo...
AbstractIt has been estimated that 10% of acute liver failure is due to “idiosyncratic hepatotoxicit...
Around 40% of drug-induced liver injury (DILI) cases are not detected in preclinical studies using t...
Toxicity studies, among them hepatotoxicity, are key throughout preclinical stages of drug developme...
Current in vitro models for hepatotoxicity commonly suffer from low detection rates due to incomplet...
A new approach was evaluated to predict the hepatotoxic potential of pharmaceuticals. For this purpo...
Drug-induced liver injury (DILI) is a major safety issue during drug development, as well as the mos...
New human pharmaceuticals are required by law to be tested in pre-clinical studies in order to predi...
New human pharmaceuticals are required by law to be tested in pre-clinical studies in order to predi...
This study investigated whether integrated analysis of transcriptomics and metabolomics data increas...
This study investigated whether integrated analysis of transcriptomics and metabolomics data increas...